stoxline Quote Chart Rank Option Currency Glossary
Cidara Therapeutics, Inc. (CDTX)
0.7809  0.072 (10.08%)    12-01 16:00
Open: 0.6905
High: 0.79
Volume: 531,126
Pre. Close: 0.7094
Low: 0.681
Market Cap: 71(M)
Technical analysis
2023-12-01 4:18:53 PM
Short term     
Mid term     
Targets 6-month :  1.07 1-year :  1.25
Resists First :  0.91 Second :  1.07
Pivot price 0.74
Supports First :  0.71 Second :  0.59
MAs MA(5) :  0.71 MA(20) :  0.75
MA(100) :  0.9 MA(250) :  1.07
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  54.2 D(3) :  45.1
RSI RSI(14): 51.3
52-week High :  2.09 Low :  0.46
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CDTX ] has closed below upper band by 26.8%. Bollinger Bands are 27% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.71 - 0.71 0.71 - 0.72
Low: 0.68 - 0.69 0.69 - 0.69
Close: 0.7 - 0.71 0.71 - 0.72
Company Description

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Headline News

Thu, 30 Nov 2023
Cidara Therapeutics to Present New Preclinical Data on Novel Dual ... - Yahoo Finance

Mon, 20 Nov 2023
Cidara Therapeutics Named as a San Diego Metro Area Top ... - Yahoo Finance

Thu, 02 Nov 2023
Cidara Therapeutics Inc (CDTX) Reports Q3 2023 Financial Results - Yahoo Finance

Wed, 11 Oct 2023
Cidara Therapeutics Presents New Preclinical and Clinical Data on ... - Yahoo Finance

Sun, 06 Aug 2023
Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) Shift From Loss To Profit - Yahoo Finance

Thu, 03 Aug 2023
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 90 (M)
Shares Float 77 (M)
Held by Insiders 9.2 (%)
Held by Institutions 33.7 (%)
Shares Short 1,240 (K)
Shares Short P.Month 1,500 (K)
Stock Financials
EPS -0.39
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.09
Profit Margin -54.3 %
Operating Margin -67.3 %
Return on Assets (ttm) -30.4 %
Return on Equity (ttm) -359 %
Qtrly Rev. Growth -68.9 %
Gross Profit (p.s.) -0.13
Sales Per Share 0.62
EBITDA (p.s.) -0.35
Qtrly Earnings Growth 0 %
Operating Cash Flow -31 (M)
Levered Free Cash Flow -13 (M)
Stock Valuations
PE Ratio -2.01
PEG Ratio -0.1
Price to Book value 8.67
Price to Sales 1.24
Price to Cash Flow -2.3
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android